Evidence map›Paper›PMID 28063991›Full record

ArticleActa biomaterialia2017

The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response.

Emad I Wafa, Sean M Geary, Jonathan T Goodman, Balaji Narasimhan, Aliasger K Salem

Abstract read
In one paragraph

Article in Acta biomaterialia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Self-adjuvanting cancer nanovaccines.Journal of nanobiotechnology · 2022
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4β.Journal of biomedical materials research. Part A · 2021
    Article
  15. Review
  16. Article
  17. Polymeric Nanoparticle-Based Vaccine Adjuvants and Delivery Vehicles.Current topics in microbiology and immunology · 2021
    Review
  18. Applications of Nanovaccines for Disease Prevention in Cattle.Frontiers in bioengineering and biotechnology · 2020
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Emad I WafaDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA.
Sean M GearyDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA.
Jonathan T GoodmanDepartment of Chemical and Biological Engineering, College of Engineering, Iowa State University, Ames, IA 50011, USA.
Balaji NarasimhanDepartment of Chemical and Biological Engineering, College of Engineering, Iowa State University, Ames, IA 50011, USA.
Aliasger K SalemDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA. Electronic address: aliasger-salem@uiowa.edu.
University of Iowa · USIowa State University · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0M
The Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI LENTZ, STEVEN R · 2002 to 2021
$45.7M
Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Jong Sung Kim · 1990 to 2026
$40.5M
Obesity Affects Immunity to Kidney CancerR01CA181088 · NCI · UNIVERSITY OF IOWA · PI NORIAN, LYSE A · 2014 to 2018
$1.5M
Enhanced Shelf-life Nanovaccine Formulation for Immunity to Biodefense PathogensR01AI111466 · NIAID · IOWA STATE UNIVERSITY · PI NARASIMHAN, BALAJI · 2014 to 2017
$1.4M
Impact of polymer adjuvant chemistry on adaptive immune mechanismsR56AI075026 · NIAID · IOWA STATE UNIVERSITY · PI NARASIMHAN, BALAJI · 2010 to 2010
$537k
NCI NIH HHS P30 CA086862NCI NIH HHS P50 CA097274NCI NIH HHS R01 CA181088NIAID NIH HHS R01 AI111466NIAID NIH HHS R56 AI075026NIEHS NIH HHS P30 ES005605
6 · The paper itself

Abstract

The goal of this research was to study the effect of polyanhydride chemistry on the immune response induced by a prophylactic cancer vaccine based on biodegradable polyanhydride particles. To achieve this goal, different compositions of polyanhydride copolymers based on 1,8-bis-(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG), 1,6-bis-(p-carboxyphenoxy)-hexane (CPH), and sebacic anhydride (SA) were synthesized by melt polycondensation, and polyanhydride copolymer particles encapsulating a model antigen, ovalbumin (OVA), were then synthesized using a double emulsion solvent evaporation technique. The ability of three different compositions of polyanhydride copolymers (50:50 CPTEG:CPH, 20:80 CPTEG:CPH, and 20:80 CPH:SA) encapsulating OVA to elicit immune responses was investigated. In addition, the impact of unmethylated oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODN), an immunological adjuvant, on the immune response was also studied. The immune response to cancer vaccines was measured after treatment of C57BL/6J mice with two subcutaneous injections, seven days apart, of 50μg OVA encapsulated in particles composed of different polyanhydride copolymers with or without 25μg CpG ODN. In vivo studies showed that 20:80 CPTEG:CPH particles encapsulating OVA significantly stimulated the highest level of CD8 STATEMENT OF SIGNIFICANCE: Compared to soluble cancer vaccine formulations, tumor antigens encapsulated in biodegradable polymeric particles have been shown to sustain antigen release and provide long-term protection against tumor challenge by improving the immune response towards the antigen. Treatment of mice with cancer vaccines based on different polyanhydride copolymers encapsulating OVA resulted in stimulation of tumor-specific immune responses with different magnitudes. This clearly indicates that polyanhydride chemistry plays a substantial role in stimulating the immune response. Vaccination with 20:80 CPTEG:CPH/OVA, the most hydrophobic formulation, stimulated the strongest cellular and humoral immune responses and provided the longest survival outcome without adding any other adjuvant. The most important finding in this study is that the copolymer composition of polyanhydride particle-based vaccines can have a direct effect on the magnitude of the antitumor immune response and should be selected carefully in order to achieve optimal cancer vaccine efficacy.

Indexed as

AnimalsCancer VaccinesCD8-Positive T-LymphocytesFemaleImmunoglobulin GMice, Inbred C57BLNeoplasmsOvalbuminParticle SizePolyanhydridesProton Magnetic Resonance SpectroscopyStatic ElectricitySurvival AnalysisVaccinationCancer VaccinesImmunoglobulin GOvalbuminPolyanhydridesAdjuvantAntigenAntitumor immune responseBiodegradable polymerCancer vaccinePolyanhydrides

Identifiers

PMID28063991
PMCPMC5316298
OpenAlexW2568627235

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.